WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H414730
CAS#: 2133852-18-1
Description: Zastaprazan, also known as JP-1366, is a proton pump inhibitor. JP-1366 mediates strong, selective, and dose-dependent inhibition of H+/K+-ATPase. JP-1366 significantly suppressed gastric acid secretion in histamine-treated pylorus-ligated rats in a dose-dependent manner. Additionally, JP-1366 inhibited histamine-stimulated gastric acid secretion in the HPD model. JP-1366 exhibited a more than 2-fold higher inhibitory effect on esophageal injury than TAK-438 in GERD lesions and had a more potent inhibitory effect in indomethacin- or aspirin-induced gastric ulcer rat models than TAK-438. Additionally, JP-1366 inhibited gastric ulcers.
Hodoodo Cat#: H414730
Name: Zastaprazan
CAS#: 2133852-18-1
Chemical Formula: C22H26N4O
Exact Mass: 362.21
Molecular Weight: 362.480
Elemental Analysis: C, 72.90; H, 7.23; N, 15.46; O, 4.41
Synonym: Zastaprazan; JP-1366; JP 1366; JP1366;
IUPAC/Chemical Name: (azetidin-1-yl)(8-{[(2,6-dimethylphenyl)methyl]amino}- 2,3-dimethylimidazo[1,2-a]pyridin-6-yl)methanone
InChi Key: FEQFUBYYZYQTOJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H26N4O/c1-14-7-5-8-15(2)19(14)12-23-20-11-18(22(27)25-9-6-10-25)13-26-17(4)16(3)24-21(20)26/h5,7-8,11,13,23H,6,9-10,12H2,1-4H3
SMILES Code: O=C(N1CCC1)C2=CN3C(C(NCC4=C(C)C=CC=C4C)=C2)=NC(C)=C3C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: The global prevalence of GERD is substantially increasing each year, and GERD is a chronic disease that reduces the quality of life of patients. The efficacy of conventional drugs is diverse, and most require long-term or lifetime administration; thus, the development of more effective therapeutic agents is needed.
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 362.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Ku JM, Cho JH, Kim K, Kim JY, Kim JY, Kim J, Cha H, Cheon B. JP-1366: A novel and potent potassium-competitive acid blocker that is effective in the treatment of acid-related diseases. Pharmacol Res Perspect. 2023 Jun;11(3):e01090. doi: 10.1002/prp2.1090. PMID: 37147903; PMCID: PMC10163344.
2: Hwang I, Ji SC, Oh J, Kim H, Cha H, Kim J, Lee CS, Yu KS, Lee S. Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in healthy subjects. Aliment Pharmacol Ther. 2023 Apr;57(7):763-772. doi: 10.1111/apt.17406. Epub 2023 Feb 2. PMID: 36732884.
